



Proteomics International

LABORATORIES LTD

ASX Release

30 May 2025

ASX code: PIQ

Results of Extraordinary General Meeting

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to advise that all resolutions considered at the Extraordinary General Meeting of the Company held earlier today were passed by poll.

The results of the Extraordinary General Meeting are set out in the attached document.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Proteomics International (Europe)
Plesmanweg 9, 7602 PD Almelo
The Netherlands
T: +31 85 40 11 173
E: Europe@PromarkerD.eu

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Disclosure of Proxy Votes

Proteomics International Laboratories Ltd

Extraordinary General Meeting

Friday, 30 May 2025



GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of Prior Issue – Placement Shares	P	27,115,777	26,684,252 98.41%	385,411 1.42%	10,558,598	46,114 0.17%	27,149,464 98.60%	385,411 1.40%	11,222,030	Carried
2 Ratification of Prior Issue – Placement Options	P	27,115,777	26,669,252 98.35%	400,411 1.48%	6,761,803	46,114 0.17%	27,134,464 98.55%	400,411 1.45%	7,425,235	Carried
3 Approval of proposed issue of Director Placement Shares and Attaching Options to Director Dr Richard Lipscombe	P	29,665,334	27,985,072 94.34%	1,637,290 5.52%	16,423,774	42,972 0.14%	29,110,574 94.68%	1,637,290 5.32%	16,423,774	Carried
4 Approval of proposed issue of Director Placement Shares and Attaching Options to Director Mr Aaron Brinkworth	P	46,082,459	44,393,055 96.33%	1,643,290 3.57%	6,649	46,114 0.10%	45,521,699 96.52%	1,643,290 3.48%	6,649	Carried
5 Approval of proposed issue of Director Placement Shares and Attaching Options to Director Mr Neville Gardiner	P	46,082,459	44,393,055 96.33%	1,643,290 3.57%	6,649	46,114 0.10%	45,404,052 96.51%	1,643,290 3.49%	124,296	Carried
6 Approval of proposed issue of Director Placement Shares and Attaching Options to Director Mr Paul House	P	46,082,459	44,394,372 96.34%	1,641,973 3.56%	6,649	46,114 0.10%	45,299,152 96.50%	1,641,973 3.50%	230,513	Carried
7 Approval of proposed issue of Shares and Options to Ms Jacqueline Gray	P	46,082,459	44,393,055 96.33%	1,643,290 3.57%	6,649	46,114 0.10%	45,457,604 96.51%	1,643,290 3.49%	70,744	Carried
8 Approval of Issue of Options to Joint Lead Managers	P	29,652,931	28,713,930 96.83%	847,887 2.86%	16,436,177	91,114 0.31%	29,887,574 97.24%	847,887 2.76%	16,436,177	Carried

